Review of clinical trials on minimization and interruption of calcineurin inhibitors (CNIs) and protocols without CNIs in the transplantation of different organs (kidney, heart, and liver);Revue des essais cliniques sur la minimisation, l'arrêt et les protocoles sans inhibiteurs de la calcineurine dans la transplantation de différents organes (rein, cœur et foie)

Nephrologie et Therapeutique

Volumn 5, Issue SUPPL. 6, 2009, Pages

  Albano, L ^a  

^a PASTEUR HOSPITAL   (France)

Author keywords

Calcineurin inhibitors; Heart; Kidney; Liver; mTOR inhibitors; Mycophenolate; Nephrotoxicity; Transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN;

ACUTE GRAFT REJECTION; ARTICLE; CLINICAL PROTOCOL; DRUG SAFETY; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNE COMPLEX NEPHRITIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; NEPHROTOXICITY; PROTEINURIA;

CALCINEURIN; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; HEART TRANSPLANTATION; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION;

EID: 74549156487     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1769-7255(09)73428-5     Document Type: Article

References (64)

1. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., and Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am. J. Transplant 4 (2004) 378-383
2. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Allen R.D., and Chapman J.R. The natural history of chronic allograft nephropathy. N. Engl. J. Med. 349 (2003) 2326-2333
3. Gonwa T.A., Mai M.L., Melton L.B., Hays S.R., Goldstein R.M., Levy M.F., et al. End-Stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 72 (2001) 1934-1939
4. Ojo A.O., Held P.J., Port F.K., Wolfe R.A., Leichtman A.B., Young E.W., et al. Chronic renal failure after transplantation of a nonrenal organ. N. Engl. J. Med. 349 (2003) 931-940
5. Sénéchal M., Dorent R., du Montcel S.T., Ghossou J.J., Pavie A., Petitclerc T., et al. End-Stage renal failure and cardiac mortality after heart transplantation. Clin. Transplant. 18 (2004) 1-6
6. Asberg A., Midtvedt K., Line P.D., Narverud J., Holdaas H., Jenssen T., et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in dr-matched de novo kidney transplant recipients. Transplantation 82 (2006) 62-68
7. Vincenti F., Ramos E., Brattstrom C., Cho S., Ekberg H., Grinyo J., et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 71 (2001) 1282-1287
8. Vincenti F., Larsen C., Durrbach A., Wekerle T., Nashan B., Blancho G., et al. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353 (2005) 770-781
9. Smak Gregoor P.J., van Gelder T., van Besouw N.M., van der Mast B.J., IJzermans J.N., and Weimar W. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 70 (2000) 143-148
10. Abramowicz D., Del Carmen Rial M., Vitko S., del Castillo D., Manas D., Lao M., et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J. Am. Soc. Nephrol. 16 (2005) 2234-2240
11. Ekberg H., Grinyó J., Nashan B., Vanrenterghem Y., Vincenti F., Voulgari A., et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR study. Am. J. Transplant. 7 (2007) 560-570
12. Yoshida E.M., Marotta P.J., Greig P.D., Kneteman N.M., Marleau D., Cantarovich M., et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. A standard-dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized clinical trial. Liver Transpl 11 (2005) 1064-1072
13. Soliman T., Hetz H., Burghuber C., Györi G., Silberhumer G., Steininger R., et al. Short-Term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl. 13 (2007) 1039-1044
14. Bajjoka I., Hsaiky L., Brown K., and Abouljoud M. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors. Liver Transpl. 14 (2008) 66-72
15. Pageaux G.P., Rostaing L., Calmus Y., Duvoux C., Vanlemmens C., Hardgwissen J., et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl. 12 (2006) 1755-1760
16. Schlitt H.J., Barkmann A., Böker K.H., Schmidt H.H., Emmanouilidis N., Rosenau J., et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 357 (2001) 587-591
17. Barkmann A., Nashan B., Schmidt H.H., Böker K.H., Emmanouilidis N., Rosenau J., et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 69 (2000) 1886-1890
18. Watson C.J., Gimson A.E., Alexander G.J., Allison M.E., Gibbs P., Smith J.C., et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl. 13 (2007) 1694-1702
19. Shenoy S., Hardinger K.L., Crippin J., Desai N., Korenblat K., Lisker-Melman M., et al. Sirolimus conversion in liver transplant recipients with renal dysfunction: A prospective, randomized, single-center trial. Transplantation 83 (2007) 1389-1392
20. Fairbanks K.D., Eustace J.A., Fine D., and Thuluvath P.J. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 9 (2003) 1079-1085
21. Nair S., Eason J., and Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 9 (2003) 126-129
22. DuBay D., Smith R.J., Qiu K.G., Levy G.A., Lilly L., and Therapondos G. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transpl 14 (2008) 651-659
23. Rosenberg P.B., Vriesendorp A.E., Drazner M.H., Dries D.L., Kaiser P.A., Hynan L.S., et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J. Heart Lung Transplant 24 (2005) 1327-1331
24. Cantarovich M., Giannetti N., Barkun J., and Cecere R. Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation 78 (2004) 779-781
25. Meiser B., Reichart B., Adamidis I., Uberfuhr P., and Kaczmarek I. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am. J. Transplant 5 (2005) 827-831
26. Zuckermann A., Ploner M., Keziban U., Czerny M., Wolner E., Laufer G., et al. Benefit of mycophenolate-mofetil (MMF) in patients with cyclosporine (CYA) induced nephropathy after cardiac transplantation. J. Heart Lung Transplant 20 (2001) 163
27. Tedoriya T., Keogh A.M., Kusano K., Savdie E., Hayward C., Spratt P.M., et al. Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil. J. Heart Lung Transplant 21 (2002) 976-982
28. Sanchez V., Delgado J.F., Morales J.M., Tello R., Gómez M.A., Escribano P., et al. Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: Long-Term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplant. Proc 36 (2004) 2823-2825
29. Manito N., Kaplinsky E.J., Roca J., Castells E., Saura E., Gomez- Hospital J.A., et al. Heart transplant recipient clinical profile improvement following mycophenolate mofetil late incorporation into the treatment schedule. Clin. Transplant 19 (2005) 304-308
30. Boyer O., Le Bidois J., Dechaux M., Gubler M.C., and Niaudet P. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. Transplantation 79 (2005) 1405-1410
31. Baryalei M., Zenker D., Pieske B., Tondo K., Dalichau H., and Aleksic I. Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine. Transplant. Proc. 35 (2003) 1539-1542
32. Aleksic I., Baryalei M., Busch T., Pieske B., Schorn B., Strauch J., et al. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation 69 (2000) 1586-1590
33. Al-Aly Z., Sachdeva A., Philoctete Ashley J.M., and Bastani B. Preliminary experience with mycophenolate mofetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity. Nephrology 11 (2006) 151-155
34. Gleissner C.A., Doesch A., Ehlermann P., Koch A., Sack F.U., Katus H.A., et al. Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy. Am. J. Transplant 6 (2006) 2750-2758
35. Meiser B., Kaczmarek I., Mueller M., Groetzner J., Weis M., Knez A., et al. Low-Dose tacrolimus/sirolimus and steroid withdrawal in heart recipients is highly efficacious. J. Heart Lung Transplant 26 (2007) 598-603
36. Lehmkuhl H.B., Mai D., Dandel M., Knosalla C., Hiemann N.E., Grauhan O., et al. Observational study with everolimus (certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. Journal of Heart and Lung Transplantation 26 (2007) 700-704
37. Hunt, Bedanova, Starling. Premature termination of a prospective, open label, randomized, multicenterstudy of srl to replace cnis (CNI) in a standard care regimen of CNI, MMF and corticosteroids early after heart transplantation. J. Heart Lung Transplant 26 (2007) S203
38. Zakliczynski M., Nozynski J., Zakliczynska H., Rozentryt P., and Zembala M. Deterioration of renal function after replacement of cyclosporine with sirolimus in five patients with severe renal impairment late after heart transplantation. Transplant. Proc. 35 (2003) 2331-2332
39. Snell G.I., Levvey B.J., Chin W., Kotsimbos T., Whitford H., Waters K.N., et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J. Heart Lung Transplant 21 (2002) 540-546
40. Rothenburger M., Teerling E., Bruch C., Lehmkuhl H., Suwelack B., Bara C., et al. Calcineurin inhibitor-free immunosuppression using everolimus (certican) in maintenance heart transplant recipients: 6 months' follow-up. J. Heart Lung Transplant 26 (2007) 250-257
41. Raichlin E., Khalpey Z., Kremers W., Frantz R.P., Rodeheffer R.J., Clavell A.L., et al. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Transplantation 84 (2007) 467-474
42. Moro J., Almenar L., Martínez-Dolz L., Izquierdo M., Rueda J., Arnau M.A., et al. Mtor inhibitors and their secondary effects in cardiac transplant recipients: A descriptive study. Transplant. Proc. 39 (2007) 2365-2367
43. Lyster H., Panicker G., Leaver N., and Banner N.R. Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation. Transplant. Proc. 36 (2004) 3167-3170
44. Kushwaha S.S., Khalpey Z., Frantz R.P., Rodeheffer R.J., Clavell A.L., Daly R.C., et al. Sirolimus in cardiac transplantation: Use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J. Heart Lung Transplant. 24 (2005) 2129-2136
45. Hunt J., Lerman M., Magee M.J., Dewey T.M., Herbert M., and Mack M.J. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J. Heart Lung Transplant 24 (2005) 1863-1867
46. Gustafsson F., Ross H.J., Delgado M.S., Bernabeo G., and Delgado D.H. Sirolimus-Based immunosuppression after cardiac transplantation: Predictors of recovery from calcineurin inhibitor-induced renal dysfunction. J. Heart Lung Transplant. 26 (2007) 998-1003
47. Groetzner J., Kaczmarek I., Schulz U., Stegemann E., Kaiser K., Wittwer T., et al. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Transplantation 87 (2009) 726-733
48. Fernandez-Valls M., Gonzalez-Vilchez F., de Prada J.A., Ruano J., Ruisanchez C., and Martin-Duran R. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: Experience of a single center. Transplant. Proc. 37 (2005) 4021-4023
49. De Meester J.M., Van Vlem B., Walravens M., Vanderheyden M., Verstreken S., Goethals M., et al. Preservation of renal function after heart transplantation: Initial single-center experience with sirolimus. Transplant. Proc. 37 (2005) 1835-1838
50. Cabezón S., Lage E., Hinojosa R., Ordóñez A., and Campos A. Sirolimus improves renal function in cardiac transplantation. Transplant. Proc. 37 (2005) 1546-1547
51. Bestetti R.B., Theodoropoulos T.A.D., Burdmann E.A., Santos M.A., and Abbud-Filho M. Switch from cyclosporine to sirolimus as a treatment of acute renal failure complicating cardiogenic shock in a heart transplant recipient. Int. J. Cardiol. 112 (2006) 83-84
52. Aliabadi A.Z., Pohanka E., Seebacher G., Dunkler D., Kammerstätter D., Wolner E., et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am. J. Transplant. 8 (2008) 854-861
53. Moore J., Middleton L., Cockwell P., Adu D., Ball S., Little M.A., et al. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: A systematic review and meta-analysis. Transplantation 87 (2009) 591-605
54. Smak Gregoor P.J., de Sévaux R.G., Ligtenberg G., Hoitsma A.J., Hené R.J., Weimar W., et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study. J. Am. Soc. Nephrol. 13 (2002) 1365-1373
55. Pascual M., Curtis J., Delmonico F.L., Farrell M.L., Williams W.W., Kalil R., et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 75 (2003) 1501-1505
56. Oberbauer R., Segoloni G., Campistol J.M., Kreis H., Mota A., Lawen J., et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl. Int. 18 (2005) 22-28
57. Pearson T., Mulgaonkar S., Patel A., Scandling J., Schidban H., Weir M., et al. Efficacy and safety of mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant patients: Final results of the sparethe-nephron trial. Am. J. Transplant. (2008) 7
58. Golshayan D., and Pascual M. Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation. Transpl. Immunol. 20 (2008) 21-28
59. Afzali B., Shah S., Chowdhury P., O'sullivan H., Taylor J., and Goldsmith D. Low-Dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Transplantation 79 (2005) 304-309
60. Ducloux D., Motte G., Billerey C., Bresson-Vautrin C., Vautrin P., Rebibou J.M., et al. Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: A 2-year follow-up. Transpl. Int. 15 (2002) 387-392
61. Weir M.R., Ward M.T., Blahut S.A., Klassen D.K., Cangro C.B., Bartlett S.T., et al. Long-Term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int. 59 (2001) 1567-1573
62. Dudley C., Pohanka E., Riad H., Dedochova J., Wijngaard P., Sutter C., et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: The «creeping creatinine» study. Transplantation 79 (2005) 466-475
63. Suwelack B., Gerhardt U., and Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am. J. Transplant. 4 (2004) 655-662
64. Frimat L., Cassuto-Viguier E., Charpentier B., Noël C., Provôt F., Rostaing L., et al. Impact of cyclosporine reduction with MMF: A randomized trial in chronic allograft dysfunction. The 'reference' study. Am. J. Transplant. 6 (2006) 2725-2734